Skip to Main Content

Brian Schulte


Sarcoma medical oncologist
Science fiction reader, skier, mountain biker and runner

About me

Dr. Brian Schulte is a hematologist-oncologist who cares for patients of all ages with sarcomas, rare cancers that develop in connective tissues (such as bone, muscle or cartilage), and has particular expertise in gastrointestinal stromal tumors. Working as part of a multidisciplinary team, he strives to ensure patients receive the best possible comprehensive care.

In research, Schulte studies novel medications, alone and in combination, to treat sarcoma.

After earning a bachelor's degree in engineering at Duke University, Schulte earned his medical degree at the Medical College of Wisconsin and completed a residency in internal medicine at the University of Colorado Anschutz Medical Campus. He completed a fellowship in hematology-oncology at Northwestern University Feinberg School of Medicine, where he served as chief fellow.

  • Education

    Medical College of Wisconsin, MD, 2015

  • Residencies

    University of Colorado School of Medicine, Internal Medicine, 2018

  • Fellowships

    Northwestern University, Hematology-oncology, 2021

  • Academic Title

    Assistant Professor

My goal is to empower patients with knowledge and understanding, so they can make the best health care and treatment decisions.

Where I see patients (2)

    My reviews


    Overall Experience
    31 Ratings
    Explained things in a way that was easy to understand
    31 Ratings
    Did the doctor pay attention to your concerns
    30 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    31 Ratings
    Knew the important information about your medical history
    31 Ratings
    The provider showed respect for what you had to say
    31 Ratings
    The provider spent enough time with me
    30 Ratings
    Decorative Caduceus

    Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic A...

    ORR based on the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until disease progression as determined by IRR using...


    Decorative Caduceus

    Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

    Assess dose limiting toxicity as defined in the protocol